Concetta Mazzotta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Concetta Mazzotta has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Anna Rubegni
Molecular Medicine for Neurodegenerative and Neuromuscular Disease Unit, IRCCS Stella Maris Foundation, 56128 Pisa, Italy
1 shared publication - Enza Maria Valente
Department of Molecular Medicine, University of Pavia, 27100 Pavia, Italy
1 shared publication - Filippo Maria Santorelli
Department of Developmental Neuroscience, IRCCS Fondazione Stella Maris, 56128 Pisa, Italy
1 shared publication - Gerardo Ongari
Cellular and Molecular Neurobiology Section IRCCS Mondino Foundation Pavia Italy
1 shared publication - Roberta Battini
Department of Developmental Neuroscience, IRCCS Fondazione Stella Maris, 56128 Pisa, Italy
1 shared publication - Rosa Pasquariello
IRCCS Stella Maris Foundation, 56128 Pisa, Italy
1 shared publication
Latest Publications
- Open Access
- 14 January 2021
- Published by MDPI AG in Applied Sciences
- Vol. 11 (2) , 748
Phenotypic Definition and Genotype-Phenotype Correlates in PMPCA-Related Disease
Background: Peptidase mitochondrial processing alpha (PMPCA) biallelic mutations cause a spectrum of disorders ranging from severe progressive multisystemic mitochondrial encephalopathy to a milder non-progressive cerebellar ataxia with or without intellectual disability. Recently, we and others described an intermediate phenotype in two unrelated patients. Methods: We report a second Italian patient carrying novel PMPCA variants (p.Trp278Leu; p.Arg362Gly). Molecular modeling, dynamics simulation, RT-qPCR, and Western blotting were performed to predict the pathogenic impact of variants in the two Italian patients and attempt genotype-phenotype correlates. Results: In line with the two patients with intermediate phenotypes, our case presented global psychomotor delay with regression, intellectual disability, spastic-ataxic gait, and hyperkinetic movements, with cerebellar atrophy and bilateral striatal hyperintensities. However, blood lactate, muscle biopsy, and MRI spectroscopy were normal. PMPCA protein levels were significantly higher than controls despite normal cDNA levels. Dynamics simulation of several PMPCA missense variants showed a variable impact on the flexibility of the glycine rich loop and, for some cases, on the overall protein stability, without clear genotype-phenotype correlates. Conclusion: We confirm the expansion of PMPCA phenotypic spectrum including an intermediate phenotype of progressive encephalopathy without systemic involvement. The association of cerebellar atrophy with “Leigh-like” striatal hyperintensities may represent a “red flag” for this condition.
- 14 January 2021
- Published by MDPI AG in Applied Sciences
- Vol. 11 (2) , 748
Open AccessPhenotypic Definition and Genotype-Phenotype Correlates in PMPCA-Related Disease
Background: Peptidase mitochondrial processing alpha (PMPCA) biallelic mutations cause a spectrum of disorders ranging from severe progressive multisystemic mitochondrial encephalopathy to a milder non-progressive cerebellar ataxia with or without intellectual disability. Recently, we and others described an intermediate phenotype in two unrelated patients. Methods: We report a second Italian patient carrying novel PMPCA variants (p.Trp278Leu; p.Arg362Gly). Molecular modeling, dynamics simulation, RT-qPCR, and Western blotting were performed to predict the pathogenic impact of variants in the two Italian patients and attempt genotype-phenotype correlates. Results: In line with the two patients with intermediate phenotypes, our case presented global psychomotor delay with regression, intellectual disability, spastic-ataxic gait, and hyperkinetic movements, with cerebellar atrophy and bilateral striatal hyperintensities. However, blood lactate, muscle biopsy, and MRI spectroscopy were normal. PMPCA protein levels were significantly higher than controls despite normal cDNA levels. Dynamics simulation of several PMPCA missense variants showed a variable impact on the flexibility of the glycine rich loop and, for some cases, on the overall protein stability, without clear genotype-phenotype correlates. Conclusion: We confirm the expansion of PMPCA phenotypic spectrum including an intermediate phenotype of progressive encephalopathy without systemic involvement. The association of cerebellar atrophy with “Leigh-like” striatal hyperintensities may represent a “red flag” for this condition.